CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading compound profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Cannabinoids/Cannabidiol (CBD)

Plant cannabinoids

Cannabidiol (CBD)

An cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4.

Definition: CHEBI:69478 · Chemical Entities of Biological Interest · release 253

(1'R,2'R)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydrobiphenyl-2,6-diol(-)-cannabidiolcannabidiolcannabidiolum(-)-CBDCBDDelta(1(2))-trans-cannabidiol(-)-trans-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol(-)-trans-cannabidiol

2,614public articles

14registered condition areas

All documents →

Identity & provenance

Chemical identity

C21H30O2 · molecular weight 314.469

CAS: cas:13956-29-1↗CHEBI: CHEBI:3358↗CHEBI: CHEBI:69478↗DRUGBANK: drugbank:DB09061↗DRUGCENTRAL: drugcentral:5288↗KEGG.COMPOUND: kegg.compound:C07578↗KNAPSACK: knapsack:C00002641↗LIPIDMAPS: lipidmaps:LMPK13120001↗METACYC.COMPOUND: metacyc.compound:CPD-7173↗PATENT: patent:US2304669↗PDB_CCD: pdb-ccd:P0T↗PUBMED: pubmed:25703248↗PUBMED: pubmed:26845349↗PUBMED: pubmed:26976797↗PUBMED: pubmed:27067870↗PUBMED: pubmed:27157263↗PUBMED: pubmed:27215129↗PUBMED: pubmed:27267317↗PUBMED: pubmed:27285147↗PUBMED: pubmed:27344041↗

Sources: ChEBI · 253

0 referenced plant-occurrence records. They are identity candidates, not clinical evidence.

Experimental bioactivity

ChEMBL assay candidates

ChEMBL assay and bioactivity records are experimental candidates, not clinical facts, efficacy evidence or treatment recommendations. Showing 12 of 500 exact linked records.

Compound was evaluated for inhibition of human ERBB2 in an in vitro cell free assay measured by Caliper microfluidic capillary electrophoresis, time-resolved fluorescence resonance energy transfer method

Receptor tyrosine-protein kinase erbB-2 · Homo sapiens

AC50 > 30000.0 nM · candidate, not a clinical fact

Assay CHEMBL5291788 ↗ · Target CHEMBL1824 ↗ · Source document ↗

Compound was evaluated for inhibition of human EGFR in an in vitro cell free assay measured by Caliper microfluidic capillary electrophoresis, time-resolved fluorescence resonance energy transfer method

Epidermal growth factor receptor · Homo sapiens

AC50 > 30000.0 nM · candidate, not a clinical fact

Assay CHEMBL5291787 ↗ · Target CHEMBL203 ↗ · Source document ↗

Research areas

Conditions found alongside this compound

Document links and organism occurrence are candidates, not proof of efficacy, safety or a treatment recommendation.

Epilepsy and cannabinoids

343 matching public articles

Candidate association · not a treatment claim

Chronic pain and cannabinoids

141 matching public articles

Candidate association · not a treatment claim

Multiple sclerosis and cannabinoids

96 matching public articles

Candidate association · not a treatment claim

Parkinson disease and cannabinoids

51 matching public articles

Candidate association · not a treatment claim

Alzheimer disease and cannabinoids

57 matching public articles

Candidate association · not a treatment claim

Anxiety disorders and cannabinoids

46 matching public articles

Candidate association · not a treatment claim

Cancer pain and cannabinoids

21 matching public articles

Candidate association · not a treatment claim

Post-traumatic stress disorder and cannabinoids

35 matching public articles

Candidate association · not a treatment claim

Migraine disorders and cannabinoids

20 matching public articles

Candidate association · not a treatment claim

Inflammatory bowel diseases and cannabinoids

23 matching public articles

Candidate association · not a treatment claim

Opioid-related disorders and cannabinoids

19 matching public articles

Candidate association · not a treatment claim

Linked local records

Medicines and registered studies

Links use source-reported active ingredients or study intervention names and remain candidates, not treatment claims.

Medicines with this active ingredient

EPIDIOLEX Epidiolex Epidyolex Epidyolex EPIDYOLEX 100 MG/ML SOLUCION ORAL LEAFPRO CBDMED OIL FS QP 20% (CANNABIDIOL) OIL LEAFPRO CBDMED OIL FS QP 3% (CANNABIDIOL) OIL LEAFPRO CBDMED OIL FS QP 5% (CANNABIDIOL) OIL LEAFPRO CBDMED OIL T-FS QD 20% (CANNABIDIOL) OIL LEAFPRO CBDMED OIL T-FS QD 3% (CANNABIDIOL) OIL LEAFPRO CBDMED OIL T-FS QD 5% (CANNABIDIOL) OIL LEAFPRO CBDMED SOFTGELS FS QP 20 (CANNABIDIOL) CAPSULE, LIQUID FILLED LEAFPRO CBDMED SOFTGELS T-FS QD 20 (CANNABIDIOL) CAPSULE, LIQUID FILLED MD SCIENCE CANNABIDIOL (LIDOCAINE AND HISTAMINE DIHYDROCHLORIDE) CREAM MD SCIENCE CANNABIDIOL (LIDOCAINE AND HISTAMINE DIHYDROCHLORIDE) CREAM MELODY CLOVERSTRIP (CANNABIDIOL HEMP OIL) STRIP MELODY CLOVERSTRIP (CANNABIDIOL HEMP OIL) STRIP SATIVEX SATIVEX 2,7 MG/2,5 MG SOLUCION PARA PULVERIZACION BUCAL

Latest documents

Recent research

2026

Regulation and Use of Cannabidiol in Croatia Compared with Selected European and International Models: From Consumer Products to Clinical Practice

Journal of Clinical Medicine · Free full text

2026

Selective hippocampal transcriptional adaptation to long-term cannabidiol exposure in mice.

BMC Genomics · Free full text

2026

Metabolic effects and pharmacokinetics of oral cannabidiol (CBD) in Connemara ponies following 21 days of treatment.

Frontiers in Veterinary Science · Free full text

2026

Cannabinoid efficacy for pain: dose, chronicity and route

Frontiers in Neuroscience · Free full text

2026

Case Report: Oral and topical chronic administration of THC-rich and CBD-rich cannabis oil as palliative care in a rescued horse with open wound, sarcoid and chronic pain.

Frontiers in Veterinary Science · Free full text

2026

Quasi-randomization to Cannabinoid Condition in Studies of US Legal Market Cannabis: Characteristics of Accepters Versus Decliners of Condition Assignment.

Prevention Science · Free full text

2026

Navigating dose-effect complexities and challenges in cannabinoid therapy for aging-related neurobiological changes.

Frontiers in Pharmacology · Free full text

Ontology definitions normalize terms; they do not establish medical claims.

Binding affinity towards human GHSR in an in vitro assay with cellular components measured by scintillation proximity assay

Growth hormone secretagogue receptor type 1 · Homo sapiens

AC50 > 30000.0 nM · candidate, not a clinical fact

Assay CHEMBL5291803 ↗ · Target CHEMBL4616 ↗ · Source document ↗

Compound was evaluated for inhibition of rat Ptgs1 in an in vitro cell free assay measured by fluorescence spectroscopy

Prostaglandin G/H synthase 1 · Rattus norvegicus

AC50 = 771.4 nM · candidate, not a clinical fact

Assay CHEMBL5291868 ↗ · Target CHEMBL4042 ↗ · Source document ↗

Binding affinity towards human AGTR1 in an in vitro assay with cellular components measured by scintillation proximity assay

Type-1 angiotensin II receptor · Homo sapiens

AC50 > 30000.0 nM · candidate, not a clinical fact

Assay CHEMBL5291744 ↗ · Target CHEMBL227 ↗ · Source document ↗

Binding affinity towards human CCKAR in an in vitro assay with cellular components measured by scintillation proximity assay

Cholecystokinin receptor type A · Homo sapiens

AC50 = 18330.3 nM · candidate, not a clinical fact

Assay CHEMBL5291757 ↗ · Target CHEMBL1901 ↗ · Source document ↗

Binding affinity towards human EDNRA in an in vitro assay with cellular components measured by scintillation proximity assay

Endothelin-1 receptor · Homo sapiens

AC50 > 30000.0 nM · candidate, not a clinical fact

Assay CHEMBL5291785 ↗ · Target CHEMBL252 ↗ · Source document ↗

Agonist activity at human DRD1 in an in vitro cell-based assay measured by time-resolved fluorescence resonance energy transfer method

D(1A) dopamine receptor · Homo sapiens

AC50 > 30000.0 nM · candidate, not a clinical fact

Assay CHEMBL5291777 ↗ · Target CHEMBL2056 ↗ · Source document ↗

Antagonist activity at human DRD1 in an in vitro cell-based assay measured by time-resolved fluorescence resonance energy transfer method

D(1A) dopamine receptor · Homo sapiens

AC50 = 10000.0 nM · candidate, not a clinical fact

Assay CHEMBL5291778 ↗ · Target CHEMBL2056 ↗ · Source document ↗

Binding affinity towards human MC3R in an in vitro assay with cellular components measured by scintillation proximity assay

Melanocortin receptor 3 · Homo sapiens

AC50 = 25000.0 nM · candidate, not a clinical fact

Assay CHEMBL5291831 ↗ · Target CHEMBL4644 ↗ · Source document ↗

Compound was evaluated for inhibition of human PDE4D in an in vitro cell free assay measured by scintillation proximity assay

3',5'-cyclic-AMP phosphodiesterase 4D · Homo sapiens

AC50 > 30000.0 nM · candidate, not a clinical fact

Assay CHEMBL5291858 ↗ · Target CHEMBL288 ↗ · Source document ↗

Binding affinity towards human MLNR in an in vitro assay with cellular components measured by scintillation proximity assay

Motilin receptor · Homo sapiens

AC50 = 20493.9 nM · candidate, not a clinical fact

Assay CHEMBL5291833 ↗ · Target CHEMBL2203 ↗ · Source document ↗

Attribution: ChEMBL, EMBL-EBI. This normalized record block remains under CC BY-SA 3.0; adaptations must remain share-alike.

Alcohol use disorders and cannabinoids

20 matching public articles

Candidate association · not a treatment claim

Depressive disorders and cannabinoids

14 matching public articles

Candidate association · not a treatment claim

Bipolar disorder and cannabinoids

5 matching public articles

Candidate association · not a treatment claim

Registered studies

473 exact source-intervention matches.

Protocol onlyNOT_YET_RECRUITING

A Phase 3b/4, Interventional, Prospective, Multicenter, Open-Label Study Evaluating the Effectiveness of a Gradual Titration Regimen to Optimize CBD-OS as Add-On Therapy in Adults With Lennox-Gastaut Syndrome

Cannabidiol Oral Solution

Protocol onlyRECRUITING

Safety and Efficacy of Cannabidiol (CBD) for Symptoms of Post-Traumatic Stress Disorder (PTSD) in Adults Using Liquid StructureTM Formulation (NantheiaTM ATL5).

Cannabidiol Administered as Nantheia ATL5

Protocol onlyRECRUITING

Efficacy and Safety of Cannabidiol for Pain Relief of Patients With End-stage Metastatic Castration Resistant Prostate Cancer - a Randomised Double-blinded Placebo-controlled Phase II Trial

Cannabidiol

Protocol onlyRECRUITING

Effects of Full-spectrum Cannabidiol on Alcohol Consumption and Alcohol Use Disorder Phenotypes: Implications for Precision Medicine

Broad-Spectrum Cannabidiol (CBD)

Protocol onlyRECRUITING

Cannabinoid Modulation for Neurogenic Lower Urinary Tract Dysfunction in Spinal Cord Injury

CBD

Protocol onlyRECRUITING

Randomized, Double-Blind, Placebo-Controlled Cross-Over Study to Evaluate the Effects of Cannabidiol on Neurobehavioral and Function Outcomes in Sanfilippo Syndrome

Epidiolex

Protocol onlyRECRUITING

The Differential Effects of THC vs. CBD on Cognition in Persons With MS

CBD

Protocol onlyRECRUITING

Pathophysiological Mechanisms of Cannabidiol in Stress Regulation

Cannabidiol

Protocol onlyRECRUITING

CardiolRxTM in Recurrent Pericarditis (MAVERIC Phase 3) A Randomized, Double-blind, Placebo-controlled Trial

CardiolRx

Protocol onlyRECRUITING

Evaluation of Oral THC and CBD in Oral Fluid, Pharmacokinetics, and Subjective and Neurocognitive Effects in Men and Women

CBD

Protocol onlyCOMPLETED

The Effect of Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following Total Knee Arthroplasty: A Multicenter, Randomized Pilot Trial

MPL-001 (CBD: THC 25:1)

Protocol onlyRECRUITING

Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee

Cannabidiol (CBD)

Browse all matching studies →

2026

A Comparative Analysis of the Action Mechanisms of Cannabidiol, Cannabigerol, and Cannabinol in Human Cholangiocarcinoma Cell Lines.

Molecules · Free full text

2026

Combined extraction and spray-freeze-drying of Cannabis sativa Flos provides stable lyophilizate particles of cannabinoids.

Journal of Cannabis Research · Free full text

2026

Bioactivity and Regenerative Potential of Cannabidiol in Human Dental Pulp Stem Cells: A Scoping Review of In Vitro Studies.

The Scientific World Journal · Free full text

2026

Solubility-improved and antitumor activity of (-)-cannabidiol conjugates.

Journal of Cannabis Research · Free full text

2026

Herbal Formula IM-B Possesses Antioxidant Activities and Reduces Expression of Proinflammatory Cytokines in Lipopolysaccharide-Stimulated RAW 264.7 Macrophages.

Scientifica · Free full text